This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below
DUODOPA (levodopa/carbidopa intestinal gel)
DUODOPA
(levodopa/carbidopa intestinal gel)
PRODUODOPA (foslevodopa/foscarbidopa solution for infusion)
PRODUODOPA
(foslevodopa/foscarbidopa solution for infusion)
Timing matters: Bring device-aided therapies (DATs) early into the conversation1,2
Contact us
PRODUODOPA is a device aided therapy option for suitable advanced PD patients. Please complete the form below and a member of the PRODUODOPA team will get back to you.
Please fill in your details below only if you are a UK registered healthcare professional and would like to request a meeting with an AbbVie representative.
What might be the impact of advanced PD on your patients?
Supported by the 5-2-1 criteria, you can:
PRODUODOPA is indicated for the treatment of advanced levodopa-responsive PD with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson’s medicinal products have not given satisfactory results.3
DUODOPA is indicated for the treatment of advanced levodopa-responsive PD with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson’s medicinal products have not given satisfactory results.4
DAT=device-aided therapy; PD=Parkinson’s disease.
- Mills J, Martin A. Br J Neurosci Nurs. 2015;11(2):92–7.
- Thanvi BR, Lo TCN. Postgrad Med J. 2004;80(946):452–8.
- PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) UK Summary of Product Characteristics.
- DUODOPA (levodopa/carbidopa intestinal gel) UK Summary of Product Characteristics.
By clicking the links above you will leave the AbbVie Pro website and be taken to the eMC PI portal website
UK-PRODD-260091. Date of preparation: March 2026
